Defining the potential for cell therapy for vascular disease using animal models.
Cell-based therapeutics are currently being developed for a wide array of unmet medical needs. As obstructive vascular disease is the major cause of mortality in the world, cell-based strategies aimed at developing novel therapies or improving current therapies are currently under study. These studies are based on the evolving understanding of the biology of vascular progenitor cells, which has in turn led to the availability of well-defined sources of vascular cells for delivery. Crucial to the development of these approaches is the preclinical testing of cell delivery in animal models. This review highlights the crucial steps involved in the selection of cell sources and generation, delivery approaches, animal models to be used, and endpoints to be studied, in the context of cell delivery for vascular disease. Furthermore, the development of cell delivery to induce angiogenesis in ischemic limbs and to improve the response to large vessel injury will be discussed.
Gulati
Rajiv
R
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Simari
Robert D
RD
D000818:Animals; D017690:Cell Transplantation; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D007511:Ischemia / Q000473:pathology; D009389:Neovascularization, Pathologic; D010641:Phenotype; D012107:Research Design; D014652:Vascular Diseases / Q000503:physiopathology / Q000628:therapy*